{
    "pmcid": "9869787",
    "qa_pairs": {
        "How many mutations in the receptor-binding domain (RBD) does the Omicron variant have compared to previous variants like Beta and Delta?": [
            "15 mutations",
            "10 mutations",
            "20 mutations",
            "5 mutations"
        ],
        "What is the main advantage of using nanobodies derived from camelid antibodies for neutralizing SARS-CoV-2 variants?": [
            "Their small size, stability, and ability to bind unique epitopes inaccessible to conventional antibodies.",
            "Their ability to be rapidly produced in large quantities using bacterial expression systems.",
            "Their capacity to induce a strong immune response when used as a vaccine component.",
            "Their inherent resistance to degradation by human proteases."
        ],
        "What method was used to identify the binding epitopes of the nanobodies?": [
            "Peptide-based ELISA and molecular docking simulations.",
            "X-ray crystallography and mass spectrometry.",
            "Cryo-electron microscopy and nuclear magnetic resonance.",
            "Flow cytometry and western blotting."
        ],
        "What was the purpose of attaching nanobodies to a lumazine synthase (AaLS) protein cage nanoparticle?": [
            "To enhance the potency and stability of the nanobodies.",
            "To increase the nanobodies' solubility in aqueous solutions.",
            "To facilitate the delivery of nanobodies across the blood-brain barrier.",
            "To improve the specificity of nanobodies for the ACE2 receptor."
        ],
        "Which nanobody showed the highest neutralizing activity against the Omicron pseudovirus in the study?": [
            "B-B2",
            "C-C3",
            "A-A1",
            "D-D4"
        ]
    }
}